Low impact
Novo Nordisk's stock declined after announcing a Phase 3 trial failure.
MarketWatch07/31, 08:54 PM
Related assets
Coming up for NOVO
Explore next
Latest NOVO news
Finnhub08/19, 05:10 PM
FirstSquawk08/04, 11:41 PM
FirstSquawk08/04, 11:41 PM